£249.99

Springer CNS Neuroprotection: 155 (Handbook of Experimental Pharmacology, 155)

Price data last checked 57 day(s) ago - refreshing...

View at Amazon

Price History & Forecast

Last 34 days • 34 data points (No recent data available)

Historical
Generating forecast...
£249.99 £237.49 £242.49 £247.49 £252.49 £257.49 £262.49 25 January 2026 02 February 2026 10 February 2026 18 February 2026 27 February 2026

Price Distribution

Price distribution over 34 days • 1 price levels

Days at Price
34 days 0 9 17 26 34 £250 Days at Price

Price Analysis

Most common price: £250 (34 days, 100.0%)

Price range: £250 - £250

Price levels: 1 different prices over 34 days

Description

"CNS neuroprotection" was a common subject of papers, symposia, and reviews during the previous "decade of the brain. " Indeed, in recent years, experimental study of putative neuroprotective agents prompted clinical trials of numerous drug candidates in acute and chronic human neurodegenerative conditions. While the outcomes of these trials have not been as successful as initially hoped, these were early explorations, and the pipeline of relevant ideas continues to grow in strength and depth. We predict that early in this new millennium, crippling disorders such as stroke and Alzheimer's disease will be treated effectively by therapeutic neuroprotective strategies. This volume of the Handbook of Experimental Pharmacology titled eNS Neuroprotection provides a pharmacological perspective on currently promis ing neuroprotective approaches, and a clinical perspective on the challenges involved in establishing the efficacy of these approaches through appropriate clinical trials. Section I, "Mechanistic Approaches to CNS Neuroprotection," reviews major injury mechanisms that have formed the basis for many past and present clinical trials conducted around the world. Dr. KIM and colleagues, Washington University School of Medicine, review the status of blocking excitotoxicity as an approach to CNS neuroprotection. Dr. WANG, Pfizer Global Research and Development,Ann Arbor Laboratories, outlines evidence supporting a contri bution of apoptosis to pathological neuronal or glial cell loss. Drs. BECKER and HALLENBECK, University of Washington and the National Institute on Neuro logical Diseases and Stroke, respectively, argue that inhibiting inflammatory pathways in the brain can be neuroprotective. Dr.

Product Specifications

Barcode

No barcode data available

Similar Products You Might Like

The Handbook of Neuroprotection
94% match

The Handbook of Neuroprotection

Humana

£109.79 30 Jan 2026
Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets: 15 (Advances in Neurobiology, 15)
93% match

Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets: 15 (Advances in Neurobiology, 15)

Springer

£201.98 12 Jan 2026
Molecular and Cellular Biology of Neuroprotection in the CNS: 513 (Advances in Experimental Medicine and Biology, 513)
93% match

Molecular and Cellular Biology of Neuroprotection in the CNS: 513 (Advances in Experimental Medicine and Biology, 513)

Springer

£147.91 08 Apr 2026
Handbook of Neurotoxicity
93% match

Handbook of Neurotoxicity

£400.00 11 Jan 2026
Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations
93% match

Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations

Wiley

£207.59 10 Feb 2026
Neuroprotective Agents and Cerebral Ischaemia (Volume 40) (International Review of Neurobiology, Volume 40)
93% match

Neuroprotective Agents and Cerebral Ischaemia (Volume 40) (International Review of Neurobiology, Volume 40)

Academic Press

£86.98 27 Feb 2026
The Pharmacology of Neurogenesis and Neuroenhancement (Volume 77) (International Review of Neurobiology, Volume 77)
93% match

The Pharmacology of Neurogenesis and Neuroenhancement (Volume 77) (International Review of Neurobiology, Volume 77)

Academic Press

£134.79 13 Apr 2026
Neuroprotective Agents: Seventh International Conference, Volume 1053 (Annals of the New York Academy of Sciences)
93% match

Neuroprotective Agents: Seventh International Conference, Volume 1053 (Annals of the New York Academy of Sciences)

Wiley-Blackwell

£92.85 27 Feb 2026
Springer Physiology, Pharmacology and Pathology of the BBB 273
93% match

Springer Physiology, Pharmacology and Pathology of the BBB 273

Springer

£113.48 19 Apr 2026
Excitotoxicity in Neurological Diseases: New Therapeutic Challenge
93% match

Excitotoxicity in Neurological Diseases: New Therapeutic Challenge

Springer

£110.66 08 Jan 2026
Neuroprotective Therapy for Stroke and Ischemic Disease (Springer Series in Translational Stroke Research)
92% match

Neuroprotective Therapy for Stroke and Ischemic Disease (Springer Series in Translational Stroke Research)

Springer

£136.01 24 Jan 2026
Psychopharmacology of Neurologic Disease: Handbook of Clinical Neurology Series (Volume 165)
92% match

Psychopharmacology of Neurologic Disease: Handbook of Clinical Neurology Series (Volume 165)

Elsevier

£174.59 26 Feb 2026
Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic (Contemporary Neuroscience)
92% match

Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic (Contemporary Neuroscience)

Humana

£150.58 30 Mar 2026
Advances in Neuropharmacology: Drugs and Therapeutics
92% match

Advances in Neuropharmacology: Drugs and Therapeutics

CRC Press

£76.70 17 Mar 2026
Acute Neuronal Injury: The Role of Excitotoxic Programmed Cell Death Mechanisms
92% match

Acute Neuronal Injury: The Role of Excitotoxic Programmed Cell Death Mechanisms

Springer

£163.12 10 Mar 2026
Springer Animal Models of Neurological Disorders Textbook
92% match

Springer Animal Models of Neurological Disorders Textbook

Springer

£112.79 18 Apr 2026
Intracellular Traffic and Neurodegenerative Disorders (Research and Perspectives in Alzheimer's Disease)
92% match

Intracellular Traffic and Neurodegenerative Disorders (Research and Perspectives in Alzheimer's Disease)

Springer

£98.00 15 Jan 2026
Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases
92% match

Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases

Springer

£179.99 22 Jan 2026
The Neuronal Environment: Brain Homeostasis in Health and Disease (Contemporary Neuroscience)
92% match

The Neuronal Environment: Brain Homeostasis in Health and Disease (Contemporary Neuroscience)

Humana

£146.92 26 Jan 2026
The Neuronal Environment: Brain Homeostasis in Health and Disease (Contemporary Neuroscience)
92% match

The Neuronal Environment: Brain Homeostasis in Health and Disease (Contemporary Neuroscience)

Humana

£77.69 25 Jan 2026
The Handbook of Neuroprotection (Springer Protocols Handbooks)
92% match

The Handbook of Neuroprotection (Springer Protocols Handbooks)

Humana

£133.00 08 Apr 2026
Neuroprotective Signal Transduction (Contemporary Neuroscience)
92% match

Neuroprotective Signal Transduction (Contemporary Neuroscience)

Humana

£80.61 24 Jan 2026
Controlled Clinical Trials in Neurological Disease: 1 (Foundations of Neurology, 1)
92% match

Controlled Clinical Trials in Neurological Disease: 1 (Foundations of Neurology, 1)

Springer

£241.84 13 Jan 2026
Controlled Clinical Trials in Neurological Disease: 1 (Foundations of Neurology, 1)
92% match

Controlled Clinical Trials in Neurological Disease: 1 (Foundations of Neurology, 1)

Springer

£211.51 14 Jan 2026